Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics - Seite 2

ABI has been approached by a diverse roster of institutions seeking to collaborate in Covid-19 related research.  These parties include Chinese health authorities, foreign governments, international CRO firms and researchers familiar with our work in low-dose IFN.  ABI is currently in discussions with certain third-party sponsors interested in supporting the company’s late stage, clinical trial drug development program.  “We are confident in securing a long-term strategic arrangement that will not only define the continuation for the origination of specially-formulated IFN product but also construct a value chain infrastructure offering drug development turnkey services.  We envision the creation of a powerhouse organization to reestablish ABI as the foremost authority in the field of low-dose interferon,” said Stephen T. Chen, Ph.D., Chairman & CEO of ABI.  

The company is extremely encouraged by recent positive medical research that continues to demonstrate low-dose IFN’s potential promise for protecting susceptible healthy people during the coronavirus pandemic. One compelling study, though yet to be peer reviewed, is an experimental trial of recombinant human IFN alpha nasal drops to prevent Covid-19 in medical hospital staff in Hubei Province, China.  Data from this research showed that among nearly 3,000 front line nurses and doctors, a 28-day incidence of Covid-19 was zero in both the high and low-risk groups and the incidence of new-onset clinical symptoms for pneumonia was also zero. There were no adverse reactions observed.

ABI has recently assembled an experienced research management team and secured interferon sources to initiate clinical studies in the U.S., China, Taiwan and Australia.  The company will seek to work with global partners to develop its VELDONA technology for the treatment and prevention of Covid-19.  We have reconnected with research and medical experts that are avid supporters of the VELDONA drug program and together plan to orchestrate a concerted effort to support the advancement of various low-dose IFN formulations and delivery modalities that can help stem further spread of the pandemic.  Moreover, in order to better support other independent drug developers in facilitating a quicker path to market for their own respective interferon research, ABI has decided to offer its drug technology research as an open collaboration platform for the prevention and treatment of Covid-19, along with other future viral outbreaks.  The company will also out-license VELDONA with new partners to continue development of high-probability interferon therapeutics for several disease indications it has already progressed.  For instance, ABI plans to resume its late-stage clinical trials for thrombocytopenia, an immune condition causing low platelets, in which the company owns several related patents to alleviate recurrence of hepatitis C in patients.  Our open source platform will offer partners the ability to optimize the development process by accessing ABI’s thirty-plus years of valuable clinical data to selectively target suitable disease indications.  ABI extends an open invitation to any interested organizations seeking to collaborate in this endeavor.